CMED Group joins AIXIAL


AIXIAL has announced the acquisition of UK headquartered CMED Group by ALTEN EUROPE. CMED is a technology led CRO that specializes in full-service oncology, immuno-oncology, cell therapy and rare diseases, and provision of data and analytic services. CMED also has a technology division that is the developer of encapsia, a clinical data suite purpose designed to support traditional, decentral, virtual and hybrid clinical trials.

AIXIAL Group continues to build a global presence in size and scale with over 1,000 employees across the United States and Europe.

For more information, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.